Anticoagulation Flashcards
HAS-BLED
Hypertension (SBP >160)
Abnormal renal or hepatic function
Stroke history
Bleeding tendency or predisposition
Labile INR
Elderly (>65)
Drug or alcohol excess
Renal = chronic dialysis, renal transplant, SCr >= 2.26
Hepatic = Chronic hepatic disease, bilirubin >2x ULN, AST/ALT/ALP >3x ULN
Initiate warfarin 2-3mg in these groups
-Advanced age
-Low body weight (<45kg)
-Drug interactions
-Malnutrition
-Heart failure
-Hyperthyroid
-Low albumin, liver disease
-Ethnic groups (Asian)
Ideal Time in Therapeutic Range (TTR)
65-70%
S warfarin metabolism, common DI
CYP2C9 > CYP3A4
metronidazole, bactrim, fluconazole, isoniazid, fluoxetine, sertraline, amiodarone
R warfarin metabolism, common DI
CYP1A2, CYP3A4 > CYP2C19
clarithromycin/erythromycin, azoles, fluoxetine, amiodarone, cyclosporine, sertraline, grapefruit juice, FQs, PIs, diltiazem/verapamil, isoniazid, metronidazole
Dabigatran dosing, adjustment AFIB
Standard: 150mg BID
CrCl 15-30 ml/min: adjust to 75mg BID
CrCl 30-50 ml/min IN combo with ketoconazole or dronaderone: adjust to 75mg BID
Avoid dabigatran
CrCl <15 ml/min
Dialysis
CrCl 15-30 ml/min IN COMBO with verapamil, ketoconazole, dronedarone, clarithromycin
P-gp inducers (rifampin)
Chemo agents
Chemo agents that interact with all DOACs
Vinblastine, doxorubicin, imatinib, crizotinib, vandetanib, sunitinib, abiraterone, enzalutamide
Dabigatran metabolism
Renal, interactions occur w/ P-gp
Rivaroxaban dosing, adjustment AFIB
Standard: 20mg daily with food
CrCl 15-50 ml/min or dialysis: adjust to 15mg daily with food
Avoid rivaroxaban
Strong CYP3A4 and P-gp inducers or inhibitors
Chemo agents
Apixaban dosing, adjustments AFIB
Standard: 5mg BID
Adjust to 2.5mg BID:
If 2/3 criteria met (>= 80 y/o, weight <=60kg, SCr >= 1.5),
Use with strong CYP3A4 and P-gp inhibitors
Dialysis
Avoid apixaban
Strong CYP3A4 and P-gp inducers
Strong CYP3A4 and P-gp inhibitors (dose reduce or avoid if already on 2.5mg BID)
Chemo
Edoxaban dosing, adjustment AFIB
Standard: 60mg daily
CrCl 15-50 ml/min: adjust to 30mg daily
Avoid edoxaban
CrCl > 95 ml/min
CrCl < 15 ml/min
Dialysis
P-gp inducers
Chemo
Dabigatran to Warfarin conversion
CrCl >= 50 = initiate warfarin 3 days before discontinuing
CrCl 31-50 = initiate warfarin 2 days before discontinuing
CrCl 15-30 = initiate warfarin 1 day before discontinuing
Warfarin to Dabigatran
D/C warfarin, initiate dabigatran when INR <2.0
Dabigatran to Parenteral Anticoagulant
Wait 12 hr (CrCl > 30) or 24 hr (CrCl <30) after dabigatran to initiate parenteral
Parenteral Anticoagulant to Dabigatran
Initiate dabigatran 0-2 hours before next dose of parenteral dose due OR when UFH is discontinued
Rivaroxaban or Apixaban to Warfarin
D/C rivaroxaban. Start parenteral anticoagulant and warfarin as bridge
Warfarin to Rivaroxaban
D/C warfarin, start rivaroxaban when INR <3.0
Parenteral Anticoagulant to Rivaroxaban
Initiate rivaroxaban 0-2 hours before next scheduled administration
If on UFH, D/C heparin and start rivaroxaban at the same time
Warfarin to Apixaban
D/C warfarin and start apixaban when INR <2.0
Parenteral Anticoagulant to Apixaban
D/C anticoagulant and start apixaban at usual time of next dose
If on UFH infusion, DC infusion and start apixaban at same time
Edoxaban to Warfarin
If on edoxaban 60mg: reduce to 30mg and start warfarin at the same time. Once daily INR >=2.0, d/c edoxaban
If on edoxaban 30mg: reduce to 15mg and follow same as above
OR
D/C edoxaban and bridge warfarin with parenteral anticoag
Warfarin to Edoxaban
D/C warfarin and start edoxaban when INR <= 2.5
Parenteral Anticoagulant to Edoxaban
D/C anticoagulatn and start edoxaban at next scheduled time
If UFH, d/c infusion and start edoxaban 4 hours later
Trial results for DOAC vs Warfarin in AFIB
-Noninferior for stroke/stroke embolism
-ALL DOACS significantly lower rate of hemorrhagic stroke
-Dabigatran only DOAC w/ sig reduction of ischemic stroke
-Apixaban/edoxaban had sig reduction in major bleeding
-Apixaban only agent to show sig reduction in mortality compared to warfarin
Avoid/Caution DOACs in AFIB
Pregnancy
Breastfeeding
Severe hepatic dysfunction (Child-Pugh B or C)
Antiphospholipid syndrome
Bariatric surgery (Variable PKs)
Caution in obesity (BMI >40) or low body weight
Surgical Aortic Bioprosthetic Valve anticoag
Lifelong aspirin 81mg
Warfarin 2.0-3.0 if low bleed risk for 3-6 months
Transcatheter Aortic Valve implantation anticoag
Lifelong aspirin 81mg
Low risk of bleed: aspirin + clopidogrel x3-6 months
OR
Warfarin 2.0-3.0 x3-6 months
Mitral bioprosthetic valve anticoag
Lifelong aspirin 81mg
Low risk of bleed: warfarin 2.0-3.0 x3-6 months
Bioprosthetic valve placement AND AFIB anticoag
-Afib onset > 3 months after valve = DOAC
-Afib onset <3 moths after valve = warfarin
Valve replacements when INR 2.5-3.5 recommended
-Aortic mechanical valve with risk factors for thromboembolism, older generation valve
-On-X aortic valve with no risks for TE (for 3 months, then reduce INR to 1.5-2.0 w/ aspirin)
-Mitral mechanical valve
-Aortic & mitral heart valve
Mechanical heart valve bridging with surgeries
-No interruption in therapy needed for minor procedure (dental, cataract)
-Interrupt w/o bridge in invasive procedure w/ mechanical aortic valve & no risk for TE
-Interrupt w/ bridge if invasive procedure w/ mechanical aortic valve w/ risk factor or mechanical mitral valve
Enoxaparin VTE ppx for orthopedic surgeries
KNEE: 30mg q12H initiated 12-24 hours after surgery
HIP: 30mg SC q12H initiated 12-24 hours after surgery OR 40mg SC q24H initiated 12 (+-3) hours before surgery
HIP FRACTURE: 30mg SC q12H initiated 12-24 hours after surgery OR 40mg SC q24H initiated 12 (+-3) hrs before surgery
Dalteparin VTE ppx for orthopedic surgeries
KNEE: 2500 units SC initiated 6-8 hours after surgery, then 5000 units SC q24h
HIP: 2500 units SC initiated 4-8 hours after surgery, then 5000 units SC q24H OR 5000 units SC q24h initiated evening before surgery
HIP FRACTURE: insufficient evidence
Fondaparinux VTE ppx for orthopedic surgeries
KNEE, HIP, AND HIP FRACTURE
2.5mg SC q24h initiated 6-8 hours after surgery